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Background: The CD4 binding site (CD4bs) of envelope glycoprotein (Env) gp120 is a functionally conserved,
important target of anti-human immunodeficiency virus type 1 (HIV-1) neutralizing antibodies. Two neutralizing
human monoclonal antibodies, IgG1 b12 (b12) and VRC01, are broadly reactive neutralizing antibodies which
recognize conformational epitopes that overlap the CD4bs of Env gp120; however, many CRF01_AE viruses are
resistant to neutralization mediated by these antibodies. We examined the mechanism underlying the b12
resistance of the viruses using CRF01_AE Env (AE-Env)-recombinant viruses in this study.
Results: Our results showed that an amino acid substitution at position 185 in the V2 region of gp120 played a
crucial role in regulating the b12 susceptibility of AE-Env-recombinant viruses by cooperating with 2 previously
reported potential N-linked glycosylation (PNLG) sites at positions 186 (N186) and 197 (N197) in the V2 and C2
regions of Env gp120. The amino acid residue at position 185 and 2 PNLG sites were responsible for the b12 resistance
of 21 of 23 (>91%) AE-Env clones tested. Namely, the introduction of aspartic acid at position 185 (D185) conferred b12
susceptibility of 12 resistant AE-Env clones in the absence of N186 and/or N197, while the introduction of glycine at
position 185 (G185) reduced the b12 susceptibility of 9 susceptible AE-Env clones in the absence of N186 and/or N197.
In addition, these amino acid mutations altered the VRC01 susceptibility of many AE-Env clones.
Conclusions: We propose that the V2 and C2 regions of AE-Env gp120 contain the major determinants of viral resistance
to CD4bs antibodies. CRF01_AE is a major circulating recombinant form of HIV-1 prevalent in Southeast Asia. Our data
may provide important information to understand the molecular mechanism regulating the neutralization susceptibility
of CRF01_AE viruses to CD4bs antibodies.
Keywords: Human immunodeficiency virus type 1, CRF01_AE, Envelope glycoprotein, gp120, IgG1 b12, VRC01,
Neutralizing antibody* Correspondence: mkameoka@port.kobe-u.ac.jp
1Thailand-Japan Research Collaboration Center on Emerging and
Re-emerging Infections (RCC-ERI), Nonthaburi, Thailand
4Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
5Department of International Health, Kobe University Graduate School of
Health Sciences, Hyogo, Japan
Full list of author information is available at the end of the article
© 2014 Utachee et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Utachee et al. Retrovirology 2014, 11:32 Page 2 of 17
http://www.retrovirology.com/content/11/1/32Background
The envelope glycoproteins (Env), gp120 and gp41, of
human immunodeficiency virus type 1 (HIV-1) play a cen-
tral role in viral transmission and mediate attachment and
incorporation of the virus into target cells through specific
interactions with the CD4 receptor and chemokine co-
receptors [1]. In addition, Env is the major target of anti-
HIV-1 neutralizing antibodies and, in particular, the CD4
binding site (CD4bs) of Env gp120 is a functionally con-
served, important target of neutralizing antibodies [2-7].
Although numerous monoclonal antibodies against
HIV-1 Env have been developed, a limited number of
broadly reactive neutralizing human monoclonal anti-
bodies (nhmAbs) have been established [8-11]. Two
nhmAbs, IgG1 b12 (b12) and VRC01, are potent and
broadly reactive neutralizing antibodies which recognize
conformational epitopes that overlap the CD4bs of HIV-1
Env gp120 [5,7,12-14]. The nhmAb, b12 was established
from a Fab (IgG1κ) phage display library generated from a
bone marrow sample from an HIV-1-infected patient
[12,15], and is able to neutralize diverse strains of HIV-1
[16,17]. In addition, b12 protects hu-PBL-SCID mice and
macaque monkeys from infection with HIV-1 and a
chimeric simian-human immunodeficiency virus (SHIV),
respectively [18-20]. Moreover, adeno-associated virus
vector-mediated gene transfer of the b12 gene protected
humanized mice from HIV infection [21]. VRC01 is a po-
tent and broadly reactive nhmAb established from an
HIV-1-infected patient, and is capable of neutralizing di-
verse HIV-1 strains [5]. VRC01 inhibits HIV-1 infection in
RAG-hu (SCID mice injected with human hematopoietic
stem cells) mice [22] and hCD4/R5/cT1 (transgenic mice
carrying the gene encoding human CD4, CCR5 and cyclin
T1) mice [23]. It has been demonstrated that serum anti-
bodies specific for the CD4bs of Env gp120 are responsible
for the potent and broad neutralization of HIV-1 strains
mediated by broadly reactive sera of HIV-1-infected
patients [3]; therefore, it is important to establish a vaccine
strategy to elicit broadly neutralizing antibodies against
CD4bs, such as b12 and VRC01 [3,5,24]. To this end, the
regulatory mechanisms underlying the susceptibilities of
various HIV-1 strains to CD4bs antibodies, b12 and
VRC01, need to be clarified.
CRF01_AE is a major circulating recombinant form
(CRF) of HIV-1 prevalent throughout Southeast Asia
[25]. In particular, CRF01_AE is responsible for more
than 80% of infection cases in Thailand [26]. Although
b12 is able to broadly neutralize HIV-1 subtypes B, C
and D clinical isolates, it poorly neutralizes many
CRF01_AE strains [5,16,27,28]. In addition, although
VRC01 neutralizes 89% of CRF01_AE strains, the
remaining 11% of the viruses are resistant to VRC01-
mediated neutralization [5]. The mechanisms of how
CRF01_AE viruses show low susceptibility or areresistant to neutralization by b12 and VRC01 are still
not fully understood, and such studies are still ongoing
[29-31]. Recently, we established a series of CRF01_AE
Env (AE-Env)-recombinant viruses [32] and studied their
neutralization susceptibility to nhmAbs including b12
[27,32]. Our study revealed that 2 potential N-linked gly-
cosylation (PNLG) sites at amino acid positions 186 and
197, designated as N186 and N197 (amino acid number-
ing is based on the Env amino acid sequence of a re-
ference strain, HXB2 [Genbank: K03455]), in the V2 and
C2 regions of AE-Env gp120 play an important role in
regulating the b12 susceptibility of AE-Env-recombinant
viruses [33]. However, many AE-Env-recombinant viruses
tested were still resistant to b12-mediated neutralization;
therefore, we examined further the mechanism underlying
the b12 resistance of AE-Env-recombinant viruses in
this study.
Results
PNLG sites at amino acid positions 301, 339, 386 and 392
of Env gp120 play no major role in the b12 susceptibility
of AE-Env-recombinant viruses
Our previous study showed the important role of 2
PNLG sites, N186 and N197, in the V2 and C2 regions
of Env gp120 in regulating the b12 susceptibility of
AE-Env-recombinant viruses [33]. Although most AE-
Env-recombinant viruses tested were originally b12 re-
sistant, the removal of N186 and/or N197 conferred
b12 susceptibility to approximately 47% (15 of 32) of
the recombinant viruses (Table 1). However, it was not
possible to confer b12 susceptibility to the remaining
53% (17 of 32) of AE-Env-recombinant viruses (Table 1),
indicating that other factors besides N186 and N197
are involved in the b12 resistance of AE-Env-
recombinant viruses. Therefore, we searched for other
determinants of the b12 susceptibility of AE-Env-
recombinant viruses in this study. First, we compared
the amino acid sequences involved in or in close prox-
imity to the b12 contact sites of gp120, based on a pre-
vious report by Wu et al. [31], between 2 groups of
AE-Env clones. One group consisted of 15 AE-Env
clones which became b12 susceptible after removing
N186 and/or N197, whereas the other group consisted
of 17 AE-Env clones which were still resistant to b12
after removing these PNLG sites (Table 1). We found
that 15 b12-susceptible AE-Env clones contained PNLG
sites less frequently at amino acid positions 301 (N301),
339 (N339) and 392 (N392) of gp120 than 17 b12-
resistant clones (Table 2). It was reported that N301
and a PNLG site at position 386 (N386) act as a glycan
shield against neutralizing antibodies and may confer
an advantage for transmission of CRF01_AE viruses from
mother to infant [34]. In addition, N301, N339, N386 and
N392 are involved in reducing the b12 susceptibility of
Table 1 The b12 susceptibility of 32 AE-Env clones before and after removing N186 and/or N197
IC50 of b12 (μg/ml)
b
PNLG sitea Mutation(s)c
Env clonea N186 N197 Wild-type N186Q N197Q N186Q/N197Q
29CC1 + a + >40d >40 0.10 8.34
45PB1 + + >40 >40 >40 1.60
45CC1 + + >40 >40 0.02 0.65
47PL1 - a + >40 0.03
55PL1 - + >40 21.90
62PL1 + + >40 >40 >40 0.77
65CC4 + + >40 1.31
99PB2 - + >40 3.65
99CC8 - + >40 0.10
101PL1 + + >40 >40 >40 12.98
102CC2 - + >40 12.20
105PB1 + + >40 >40 0.07 0.16
105PL2 - + >40 0.29
105PL3 + + >40 >40 0.03 0.24
107CC2 + + >40 0.02
21PL2 - + >40 >40
22PL1 - + >40 >40
41PB3 + + >40 >40 >40 >40
41CC1 + + >40 >40 >40 >40
47CC11 - + >40 >40
50PB2 - + >40 >40
50PL1 - + >40 >40
52PB3 - + >40 >40
52PL4 - + >40 >40
52PL7 + + >40 >40 >40 >40
60PB2 - + >40 >40
60PL2 - + >40 >40
60CC3 + + >40 >40 >40 >40
98CC2 - + >40 >40
98CC3 - + >40 >40
99PL2 - + >40 >40
104PB4 - + >40 >40
aPNLG sites at the amino acid positions 186 (N186) and 197 (N197) were present (+) or absent (-) in the wild type of AE-Env clones. Amino acid numbering is
based on the HXB2 Env gp120.
bIC50 of b12 for suppressing viral replication was calculated using GraphPad Prism 5 software. Data are shown as the means of at least two independent experiments.
cSingle or multiple amino acid mutations were introduced into AE-Env-recombinant viruses.
dIC50 is >40 μg/ml.
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the possible involvement of these PNLG sites in regulating
the b12 susceptibility of AE-Env-recombinant viruses. To
this end, a series of AE-Env mutants in which amino acid
substitutions were introduced into these residues was pre-
pared and tested their b12 susceptibility. The results
showed that the introduction of amino acid substitutionsinto these PNLG sites did not improve the b12 suscepti-
bility of selected AE-Env clones, 21PL2, 22PL1, 50PB2,
98CC2 and 104PB4 (Figure 1). In addition, the mutations,
N339Q and N386Q, rather slightly reduced the b12 sus-
ceptibility of an AE-Env clone, 98CC2 (Figure 1D). There-
fore, we concluded that these PNLG sites played no major
role in regulating the b12 susceptibility of AE-Env clones.
Table 2 PNLG sites at positions 301, 339, 386 and 392 of
gp120 in 32 AE-Env clones
PNLG sitesa
Env cloneb N301 N339 N386 N392
HXB2 NNT NNT NST NST
29CC1 NNV YTV NTT NNT
45PB1 TNV NKV NTT NNT
45CC1 KNV NKV NTT NNT
47PL1 KHT KQV NTT NHT
55PL1 NNT SEV NTT T-T
62PL1 NNT NKT NTT NST
65CC4 YET FEV NTT DNT
99PB2 -NN NET NTS NIT
99CC8 NNT NET NTS NIT
101PL1 NNT NET NTS SRT
102CC2 NNT NTT DTT DS-
105PB1 NNT NKV NTT NKT
105PL2 NNT YEV NTT DNA
105PL3 NNT NKV NTT NKT
107CC2 ESI NKT NTT SST
21PL2 NNT NET NTS NTT
22PL1 NNT NKT NTT NNT
41PB3 NNT YTV NTT NLN
41CC1 NNT YTV NTT NNT
47CC11 NNT KQV NTT NHT
50PB2 NNV TEV NTT NDT
50PL1 NNT VKV NTT NNT
52PB3 NNT NAT NTT NMT
52PL4 NNT NAT NTT NMT
52PL7 NNT NAT NTT NMT
60PB2 NNT NQT NTT NQT
60PL2 NNT NQT NTT NQT
60CC3 GNR NQT NTT NQT
98CC2 KNV NET NTT NNT
98CC3 KNV NET NTT NNT
99PL2 DNV NET NTT PGR
104PB4 NNT YKV NTS NNT
aThe potential N-linked glycosylation (PNLG) sites at amino acid positions 301
(N301), 339 (N339), 386 (N386) and 392 (N392) were present or absent in the
wild type of 32 AE-Env clones and HXB2. Amino acid sequences were aligned
using the ClustalW algorithm with slight manual adjustment, followed by
examining the potential N-linked glycosylation (PNLG) site using N-Glycosite
(www.hiv.lanl.gov). PNLG sites are shown in bold text, while (-) represents a
gap. Amino acid numbering is based on the HXB2 Env gp120.
bFifteen AE-Env clones, 29CC1, 45PB1, 45CC1, 47PL1, 55PL1, 62PL1, 65CC4,
99PB2, 99CC8, 101PL1, 102CC2, 105PB1, 105PL2, 105PL3 and 107CC2 became
b12 susceptible after removing PNLG sites, N186 and/or N197, whereas 17
AE-Env clones, 21PL2, 22PL1, 41PB3, 41CC1, 47CC11, 50PB2, 50PL1, 52PB3,
52PL4, 52PL7, 60PB2, 60PL2, 60CC3, 98CC2, 98CC3, 99PL2 and 104PB4, were
b12 resistant after removing N186 and/or N197.
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gp120 significantly alters the b12 susceptibility of
recombinant viruses containing AE-Env clones, 47CC11
and 47PL1
Among 32 AE-Env clones, 2 AE-Env clones, 47PL1 and
47CC11, showed distinct neutralization susceptibility to
b12 after the removal of N197 (Table 1), although these
AE-Env clones were derived from an HIV-1-infected indi-
vidual and showed a close phylogenetic relationship [32].
Namely, a recombinant virus containing 47PL1-N197Q
(amino acid substitution from asparagine [N] to glutamine
[Q] at position 197 in HXB2 numbering) was highly sus-
ceptible to b12 [50% inhibitory concentration (IC50) =
0.03 μg/ml], whereas the recombinant virus contain-
ing 47CC11-N197Q was resistant to b12-mediated
neutralization (Table 1). In order to search for the de-
terminants of b12 susceptibility, we compared the
amino acid sequences of Env gp120 between 47PL1
and 47CC11. Ten positions were found to be different
between b12-susceptible 47PL1 and b12-resistant
47CC11 (Figure 2, asterisks). Therefore, a series of
point mutations, H144L, G185D, N189S, I190T,
N301Q, I467T, V488I, R500M, del.NIND (deletion of
4 amino acid residues, NIND in the V2 region of
gp120) (Figure 2) or ins.D460 (insertion of an amino
acid residue D460) was introduced into 47CC11-
N197Q, and recombinant viruses containing these
AE-Env mutants were subjected to neutralization
tests. The results showed that a recombinant virus
containing 47CC11-G185D/N197Q became highly
susceptible to b12 (IC50 = 0.03 μg/ml), whereas the 9
remaining 47CC11-N197Q-derived mutants were b12
resistant, similar to 47CC11-N197Q (Figure 3A). In
addition, a mutant AE-Env clone, 47CC11-G185D,
was constructed and subjected to neutralization tests.
A recombinant virus containing 47CC11-G185D was
moderately susceptible to b12-mediated neutralization
(IC50 = 7.62 μg/ml), although the extent of b12 sus-
ceptibility was lower than that of 47CC11-G185D/
N197Q (IC50 = 0.03 μg/ml) (Figure 3A). These results
showed that an amino acid substitution, G185D, con-
ferred b12 susceptibility to an AE-Env clone, 47CC11.
In order to confirm the role of the amino acid substi-
tution at position 185 in viral neutralization suscepti-
bility to b12, a mutation, D185G, was introduced into
47PL1-N197Q, a b12-susceptible AE-Env mutant, and
its effect on viral b12 susceptibility was tested. The
result showed that a recombinant virus containing
47PL1-D185G/N197Q became b12 resistant, similar
to the wild type of 47PL1 (Figure 3B). These results
show that the amino acid residue at position 185 in
the V2 region of gp120 plays an important role in de-
termining the b12 susceptibility of 2 AE-Env clones,
47CC11 and 47PL1. Namely, aspartic acid (D185) and
Figure 1 The b12 susceptibility of N-linked glycan mutants of AE-Env clones. Amino acid substitutions, N197Q, N301Q, N339Q, N386Q and
N392Q were introduced into AE-Env clones, 21PL2 (A), 22PL1 (B), 50PB2 (C), 98CC2 (D) and 104PB4 (E). Then, the b12 susceptibility of recombinant
viruses containing wild-type and mutant AE-Env clones was evaluated as described in Methods. The results are expressed as percent neutralization,
which was calculated by determining the reduction in viral infectivity in the presence of b12 compared to that in control experiments in the absence
of b12. All data points are the means and standard errors (error bars) of at least two independent experiments.
Utachee et al. Retrovirology 2014, 11:32 Page 5 of 17
http://www.retrovirology.com/content/11/1/32glycine (G185) residues at amino acid position 185 were
responsible for the b12 susceptibility and resistance of
47PL1 and 47CC11, respectively.
Comparison of amino acid residue at position 185 of Env
gp120 among subtype B, subtype C and CRF01_AE viruses
We next studied the amino acid residue at position 185
of gp120 among HIV-1 subtype B, subtype C and
CRF01_AE viruses, which were retrieved from the HIV
sequence database. The results showed that 70.5% of B-
Env clones, and 19% and 24% of subtype C Env (C-Env)
and AE-Env clones, respectively, contained D185
(Table 3). In addition, a variation was observed in the
amino acid residue at position 185 of gp120 among C-
Env and AE-Env clones (Table 3). The majority of AE-
Env clones contained D185 (24%), glutamic acid (E185)
(27.5%), G185 (22%) or asparagine (N185) (16%) at pos-
ition 185 of gp120 (Table 3). In addition, among our 32
AE-Env clones, D185 was conserved in 66.7% (10 of 15)
of the clones which were b12 susceptible in the absence
of N186 and/or N197, while G185, N185 or E185 was
contained in 64.6% (11 of 17) of AE-Env clones which
were resistant to b12 after removing N186 and/or N197
(Table 3).The impact of the amino acid residue at position 185 of
gp120 on the b12 susceptibility of AE-Env-recombinant
viruses
We examined the role of the amino acid residue at pos-
ition 185 in the b12 susceptibility of 3 selected AE-Env-
recombinant viruses. The recombinant virus containing
an AE-Env clone, 52PL7, was b12 resistant even after
removing N186 and N197 (Figure 4A), while the recom-
binant viruses containing 62PL1 and 101PL1 became
b12 susceptible at a low level after removing N186 and
N197 (Figure 4B and C). However, the introduction of an
amino acid substitution, E185D (Figure 4A), G185D
(Figure 4B) or N185D (Figure 4C), conferred b12 suscepti-
bility to AE-Env mutants or markedly improved their b12
susceptibility. Namely, the introduction of E185D con-
ferred b12 susceptibility to an AE-Env clone, 52PL7-N18
6Q/N197Q (Figure 4A, 52PL7-E185D/N186Q/N197Q),
while a mutation, G185D or N185D markedly improved
the b12 susceptibility of 2 AE-Env clones, 62PL1-N186Q/
N197Q (Figure 4B, 62PL1-G185D/N186Q/N197Q) and
101PL1-N186Q/N197Q (Figure 4C, 101PL1-N185D/N18
6Q/N197Q). In addition, although the single amino acid
substitution, G185D, conferred b12 susceptibility to the
wild type of 62PL1 (Figure 4B, 62PL1-G185D) (IC50 =
47PL1     1 MRVRGTQRNWPNLWKWGTLILGLVIICSASDNLWVTVYYGVPVWRDADTTLFCASDAKAHKTEVHNVWATHACVPTDPNPQEIPLENVTENFNMWKNNIV 101 
47CC11    1 .................................................................................................... 101 
47PL1   102 EQMHEDVISLWDQSLKPCVKLTPLCVTLNCTEKVTPHNVTLLNASNTLGNITDEMRNCSFNITTELRDKQKKVHALFYRLDIVQIDEK----NNYSSTYR 192 
47CC11  102 ........................................H............................................G..NIND....NI.. 192 
47PL1   193 LINCNTSVIKQACPKVSFDPIPIHYCTPAGYAILKCNDKNFNGTGPCKNVSSVQCTHGIKPVVSTQLLLNGSLAEEEIIIRSENITNNAKIIIVHLNKSV 292
47CC11  193 .................................................................................................... 292 
47PL1   293 EINCTRPSKHTRTSISFAPGQAFYQTGDIIGDIRKAFCEINGTEWKQVLKQVAEKLIEHFPNKTIKFQPHSGGDLEITMHHFNCRGEFFYCNTTKLFNHT 394 
47CC11  293 ........NN.......................................................................................... 394 
47PL1   395 YINGTINETMEGLNDTIILPCKIKQIINMWQRAGQAMYAPPIRGSIKCVSNITGILLTRDSGDNDTETFRPEGGNMKDNWRSELYKYKIVQIEPLGIAPT 499 
47CC11  395 ..............................................................-....I....................V........... 499 
47PL1   500 MAKRRVVEREKRA 512 








Figure 2 Comparison of the amino acid sequences between 2 AE-Env clones, 47PL1 and 47CC11. The deduced amino acid sequences of Env
gp120 were compared between 2 AE-Env clones, 47PL1 [Genbank:EU743768] and 47CC11 [Genbank:EU743767]. The amino acid sequences were aligned
using the ClustalW algorithm with slight manual adjustment. The positions of gp120 variable (V) and conserved (C) regions are denoted in the figure.
Dots denote amino acid identity, while dashes represent gaps introduced to optimize alignment. PNLG sites are shown by underlining. The numbering
of amino acid residues is based on the amino acid sequence of HXB2 Env and is shown beside the aligned sequences. Asterisks indicate the amino acid
differences, a deletion, an insertion and an additional PNLG site found in the gp120 amino acid sequence of 47CC11 relative to that of 47PL1.
Figure 3 The b12 susceptibility of wild-type and mutant AE-Env
clones, 47CC11 and 47PL1. The b12 susceptibility of recombinant
viruses containing wild-type or mutant AE-Env clones, 47CC11 (A) and
47PL1 (B) was evaluated as described in Methods. The results are
expressed as percent neutralization, as described in the legend to
Figure 1. All data points are the means and standard errors (error bars)
of at least three independent experiments.
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improved by multiple amino acid substitutions generating
the mutants 62PL1-G185D/N186Q (IC50 = 2.32 μg/ml),
62PL1-G185D/N197Q (IC50 = 0.04 μg/ml) and 62PL1-
G185D/N186Q/N197Q (IC50 = 0.01 μg/ml) (Figure 4B).
These results suggested that 2 PNLG sites, N186 and
N197, and the amino acid residue at position 185 synergis-
tically regulated the b12 susceptibility of AE-Env clones.
We further examined the role of the amino acid residue
at position 185, N186 and N197 on the b12 susceptibility
of AE-Env clones using recombinant viruses, and the re-
sults are summarized in Tables 4 and 5. In addition, the
relative infectivity of recombinant viruses containing wild-
type or mutant AE-Env clones is shown in Tables 6 and 7.
Most recombinant viruses containing mutant AE-Env
clones maintained their infectivity, while some recombin-
ant viruses lost their infectivity after the introduction of
mutations (Tables 6 and 7). The wild types of 14 AE-Env
clones, 21PL2, 47CC11, 50PB2, 52PB3, 52PL4, 52PL7,
60PB2, 60PL2, 62PL1, 65CC4, 98CC2, 101PL1, 102CC2
and 104PB4, were b12 resistant, and these AE-Env clones
were still b12 resistant or showed comparably low levels
of b12 susceptibility in the absence of N186 and/or N197;
however, the introduction of an amino acid substitution,
G185D, N185D or E185D, to these AE-Env mutants lack-
ing N186 and/or N197, except 60PL2- and 104PB4-
Table 3 Amino acid residue at position 185 of HIV-1 Env
n D185a E185a G185a N185a Othersa
Subtype Bb 200 70.5% 6.5% 4.5% 7.5% 11%
Subtype Cb 200 19% 15% 7.5% 36% 22.5%
CRF01_AEb 200 24% 27.5% 22% 16% 10.5%
b12 susceptible CRF01_AEc 15 66.7% 13.3% 6.7% 6.7% 6.7%
b12 resistant CRF01_AEd 17 11.8% 17.6% 17.6% 29.4% 23.5%
aFrequency (%) of samples with aspartic acid residue (D185), glutamic acid residue (E185), glycine residue (G185), asparagine residue (N185) or other residues,
alanine, histidine, lysine, methionine, proline, glutamine, arginine, serine, threonine, valine or a gap (others) at amino acid position 185 of Env was estimated.
b200 env gene sequences of subtype B, C or CRF01_AE viruses with sampling dates 2008–2010, 2008–2009 or 2007–2010, respectively, were retrieved from the
HIV sequence database (www.hiv.lanl.gov). The deduced amino acid sequences were translated and examined. Accession numbers are available upon request.
cAE-Env clones which became b12 susceptible after removing N186 and/or N197.
dAE-Env clones which were b12 resistant after removing N186 and/or N197.
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ity (Table 4). In addition, the removal of N186 and/or
N197 conferred b12 susceptibility to 9 b12-resistant AE-
Env clones, 29CC1, 45CC1, 47PL1, 99PB2, 99CC8,
105PB1, 105PL2, 105PL3 and 107CC2; however, the intro-
duction of an amino acid substitution, D185G, to thoseFigure 4 The b12 susceptibility of wild-type and mutant AE-Env
clones, 52PL7, 62PL1 and 101PL1. The b12 susceptibility of
recombinant viruses containing wild-type or mutant AE-Env clones,
52PL7 (A), 62PL1 (B) and 101PL1 (C) was evaluated as described in
Methods. The results are expressed as percent neutralization, as
described in the legend to Figure 1. All data points are the means
and standard errors (error bars) of at least three independent experiments.AE-Env mutants lacking N186 and/or N197 transformed
them into b12-resistant or low-susceptible mutants (Table 5).
In addition, the introduction of a mutation, D185N or
D185E, altered the b12 susceptibility of selected AE-Env
clones, 29CC1, 45CC1, 47PL1, 105PB1 and 105PL3, to a
lesser extent than the alteration by the introduction of
D185G to the corresponding AE-Env clones (Table 5).
These results suggested that D185 is responsible for the
b12 susceptibility of AE-Env clones, while G185, N185
and E185 are responsible to a different extent for b12
resistance or the low susceptibility of AE-Env clones.
Taking together the results shown in Figures 3 and 4 as
well as in Tables 4 and 5, it is demonstrated that the
amino acid residue at position 185 in the V2 region of
gp120 plays a crucial role in the b12 resistance of AE-
Env clones by cooperating with 2 PNLG sites, N186
and N197.
Correlation between the binding efficiency and
neutralization susceptibility of AE-Env-recombinant
viruses to b12
In our previous report, it was suggested that the N-
linked glycosylation of amino acid residues at positions
186 and 197 of gp120 inhibited the binding of b12 to
gp120 molecule in a computational model of the tri-
meric structure of HIV-1 Env proteins [33]. In order to
study the mechanism of how a single amino acid substi-
tution at the position 185 of gp120 regulated the b12
susceptibility of AE-Env clones, we tested the binding ef-
ficiency of b12 to AE-Env proteins on viral particles.
The results showed that low or no binding of b12 to the
wild-type Env proteins of three selected AE-Env clones,
47CC11, 50PB2 and 52PB3, was observed (Figure 5,
closed bars). In contrast, the introduction of a single mu-
tation, G185D or N197Q, somewhat improved the binding
efficiency of b12 to these AE-Env proteins relative to the
corresponding wild-type proteins (Figure 5, left hatched
or open bars, respectively), while the introduction of
double mutations, G185D, N185D or E185D (GNE185D),
together with N197Q significantly improved the binding
Table 4 The b12 susceptibility of AE-Env clones containing G185, N185 or E185, and the derived mutants




























21PL2 >40c >40 14.64
47CC11 >40 >40 7.62 0.03
50PB2 >40 >40 0.02
52PB3 >40 >40 0.36
52PL4 >40 >40 0.27
52PL7 >40 >40 >40 >40 7.06
60PB2 >40 >40 16.19
60PL2 >40 >40 >40
62PL1 >40 >40 >40 0.77 8.26 2.32 0.04 0.01
65CC4 >40 1.31 0.38
98CC2 >40 >40 >40 5.07
101PL1 >40 >40 >40 12.98 0.14
102CC2 >40 12.20 0.23
104PB4 >40 >40 >40
aIC50 of b12 for suppressing viral replication was calculated using GraphPad Prism 5 software. Data are shown as the means of at least three
independent experiments.
bSingle or multiple amino acid mutations were introduced into AE-Env-recombinant viruses. Amino acid numbering is based on HXB2 Env gp120.
cIC50 is >40 μg/ml.
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A relative correlation was observed between the b12 bind-
ing efficiency (Figure 5) and the b12 susceptibility of AE-
Env clones in each set of wild-type and mutant clones
(Figure 3A and Table 4). These results suggested that the
amino acid residue at position 185 regulated the b12 sus-
ceptibility of AE-Env clones at the level of the binding of











29CC1 >40c >40 0.10 8.34




105PB1 >40 >40 0.07 0.16
105PL2 >40 0.29
105PL3 >40 >40 0.03 0.24
107CC2 >40 0.02 3.42
aIC50 of b12 for suppressing viral replication was calculated using GraphPad Prism 5
independent experiments.
bSingle or multiple amino acid mutations were introduced into the AE Env-recombi
cIC50 is >40 μg/ml.The amino acid residue at position 185 of gp120 does not
affect the b12 susceptibility of 5 B-Env-recombinant
viruses, while the removal of a PNLG site, N186 or N197,
improves the b12 susceptibility of 4 B-Env-recombinant
viruses
We next examined the role of amino acid residue at pos-
ition 185 and 2 PNLG sites, N186 and N197, of gp120 in











>40 12.59 >40 >40




>40 7.03 >40 >40
>40
>40 10.09 >40 >40
software. Data are shown as the means of at least three
nant virus. Amino acid numbering is based on HXB2 Env gp120.




























21PL2 321 109 23
47CC11 1080 670 617 927
50PB2 283 296 356
52PB3 1182 362 873
52PL4 398 440 535
52PL7 161 108 96 168 48
60PB2 366 404 93
60PL2 748 996 908
62PL1 297 447 495 300 696 745 533 78
65CC4 88 29 0 0 105
98CC2 437 103 579 104
101PL1 130 149 50 33 152
102CC2 1056 50 63
104PB4 207 112 452
aInfectivity of Env-recombinant virus was evaluated using U87.CD4.CXCR4 and U87.CD4.CCR5 cells. Relative infectivity of the virus was calculated by comparing it
with the luciferase activity of pNL-envCT (pNL4-3)-infected U87.CD4.CXCR4 cells, which was defined as 100 relative light units (RLU).
bSingle or multiple amino acid mutations were introduced into AE-Env-recombinant viruses. Amino acid numbering is based on HXB2 Env gp120.
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Env of pNL4-3, QH0692.42, SC422661.8 and pWITO
4160.33, were b12 susceptible, while a recombinant virus
containing that of TRO.11 was b12 resistant (Figure 6). In
addition, the wild-type Env of pNL4-3, QH0692.42 and
SC422661.8 contained D185, while that of pWITO4160.33
and TRO.11 contained E185 (data not shown). Moreover,











29CC1 573 587 773 704
45PB1 253 363 132 1




105PB1 293 94 64 106
105PL2 581 640
105PL3 355 128 146 39
107CC2 235 48 0 0 43
aInfectivity of Env-recombinant virus was evaluated using U87.CD4.CXCR4 and U87.
with the luciferase activity of pNL-envCT (pNL4-3)-infected U87.CD4.CXCR4 cells, wh
bSingle or multiple amino acid mutations were introduced into AE-Env-recombinanwhile that of QH0692.42, SC422661.8, pWITO4160.33 and
TRO.11 contained N197, but not N186 (data not shown).
We introduced an amino acid substitution at position 185;
however, the b12 susceptibility of B-Env clones was not sig-
nificantly altered by the introduction of the mutation
(Figure 6). In contrast, the removal of N186 improved
the b12 susceptibility of pNL4-3 (Figure 6A), while the











708 371 364 662
0




55 67 26 27
397
108 83 31 26
CD4.CCR5 cells. Relative infectivity of the virus was calculated by comparing it
ich was defined as 100 relative light units (RLU).
t viruses. Amino acid numbering is based on HXB2 Env gp120.
Figure 5 The binding efficiency of b12 to Env proteins on viral
particles. Recombinant viruses containing wild-type AE-Env clones,
47CC11, 50PB2 and 52PB3, a wild-type B-Env clone, pNL4-3, and
AE-Env mutants, 47CC11-G185D, 47CC11-N197Q, 47CC11-G185D/
N197Q, 50PB2-N197Q, 50PB2-N185D/N197Q, 52PB3-N197Q and 52PB3-
E185D/N197Q, were subjected to the study. The binding efficiency of
b12 to viral particle-associated Env proteins was evaluated as described
in Methods. Data are shown as the percent recovery of Gag p24
antigen, which was associated with virus-b12-magnetic bead complex
relative to the input amount in an assay. The results are presented as
the means and standard errors (error bars) of three independent
experiments. Differences among the binding efficiencies of b12 to the
wild-type and mutant AE-Env proteins were analyzed by the paired t test
and are reported when P <0.05.
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(Figure 6A, B, C and D), but not of TRO.11 (Figure 6E).
In addition, the introduction of double mutations,
E185D and N197Q, did not confer b12 susceptibility to
TRO.11 (Figure 6E), while the introduction of double
mutations, D185G and N197Q, did not alter the b12
susceptibility of QH0692.42 and SC422661.8, relative to
the introduction of a single mutation, N197Q, into
these B-Env clones (Figure 6B and C). Finally, mutant
B-Env clones, pNL4-3-N186Q/N197Q, pNL4-3-D18
5G/N197Q and pWITO4160.33-E185D/N197Q were
also constructed; however, recombinant viruses con-
taining these B-Env mutants showed no infectivity
(Table 8); therefore, we failed to test their b12 suscepti-
bility. These results suggested that the amino acid
residue at position 185 of gp120 played no major role
in the b12 susceptibility of B-Env clones. In addition, 4
of 5 wild-type B-Env clones were already highly suscep-
tible to b12 in the presence of N186 and/or N197
(Figure 6A, B, C and D), while the removal of N197 did
not confer b12 susceptibility to TRO.11 (Figure 6E).
Therefore, we consider that, although 2 PNLG sites,
N186 and N197, of gp120 play an important role in
regulating the b12 susceptibility of B-Env clones, the
role for these B-Env clones is not as significant as that
for AE-Env clones tested.Role of the amino acid residue at position 185, N186 and
N197 in the VRC01 susceptibility of AE-Env-recombinant
viruses
We next examined the role of the amino acid residue at
position 185, as well as of 2 PNLG sites, N186 and N197,
in the susceptibility of AE-Env-recombinant viruses to
VRC01-mediated neutralization. VRC01 has been re-
ported to be capable of neutralizing 89% of CRF01_AE vi-
ruses tested [5]; however, among selected AE-Env clones
tested, the wild types of 56.5% (13 of 23) of AE-Env
clones, 29CC1, 45CC1, 47PL1 and 105PL2 (Table 9) as
well as 21PL2, 47CC11, 52PB3, 52PL4, 52PL7, 60PL2,
62PL1, 102CC2 and 104PB4 (Table 10), were VRC01 re-
sistant, while those of 43.5% (10 of 23) of AE-Env
clones, 99PB2, 99CC8, 105PB1, 105PL3 and 107CC2
(Table 9), as well as 50PB2, 60PB2, 65CC4, 98CC2 and
101PL1 (Table 10), were susceptible to VRC01-
mediated neutralization. In addition, the VRC01 sus-
ceptibility of AE-Env clones, 45CC1, 99CC8, 105PL2,
105PL3 and 107CC2 (Table 9), as well as 21PL2, 50PB2,
52PB3, 52PL4, 60PB2, 60PL2, 65CC4, 98CC2, 101PL1
and 102CC2 (Table 10), was improved after the removal
of N186 and/or N197, suggesting that 2 PNLG sites,
N186 and N197, played a role in regulating the VRC01
susceptibility of some AE-Env clones tested. We next
studied the role of the amino acid residue at position
185 in the VRC01 susceptibility of AE-Env clones. The
results showed that the introduction of a mutation,
D185G, to most AE-Env mutants lacking N186 or
N197, except 45CC1- and 105PL2-derived mutants, did
not reduce the VRC01 susceptibility of AE-Env clones
(Table 9), suggesting that the amino acid residue at 185
had no major role in the VRC01 susceptibility of these
AE-Env clones. However, the introduction of a muta-
tion, G185D, N185D or E185D, to the AE-Env clones
lacking N186 and/or N197 improved the VRC01 sus-
ceptibility of AE-Env clones, 21PL2, 50PB2, 52PB3,
52PL4, 60PB2 and 102CC2 (Table 10), while the introduc-
tion of the mutation did not affect significantly or rather
reduced the VRC01 susceptibility of the remaining AE-Env
clones, 47CC11, 52PL7, 60PL2, 62PL1, 65CC4, 98CC2,
101PL1 and 104PB4 (Table 10). These results suggested
that the amino acid residue at position 185, as well as 2
PNLG sites, N186 and N197, regulated the susceptibility of
some AE-Env clones to VRC01-mediated neutralization;
however, their role in VRC01 susceptibility is not as signifi-
cant as that for the b12 susceptibility of AE-Env clones.
Discussion
Amino acid mutations and N-linked glycosylation of par-
ticular amino acid residues affect the protein structure
and change the neutralization susceptibility of HIV-1 Env
[39,40]. Although several reports describe the role of
PNLG sites involved in or in close proximity to the b12
Figure 6 The b12 susceptibility of wild-type and mutant B-Env clones. The b12 susceptibility of recombinant viruses containing wild-type or
mutant B-Env clones, pNL4-3 (A), QH0692.42 (B), SC422661.8 (C), pWITO4160.33 (D) and TRO.11 (E) was evaluated as described in Methods. The results
are expressed as percent neutralization, as described in the legend to Figure 1. All data points are the means and standard errors (error bars) of at least
two independent experiments.
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of subtype B viruses [31,34-38], the PNLG sites, N301,
N339, N386 and N392, had no major role in the b12 sus-
ceptibility of AE-Env-recombinant viruses (Figure 1). We
therefore searched for other determinants of the b12 re-
sistance of AE-Env clones using recombinant viruses and
found that a single amino acid substitution at position 185
in the V2 region of gp120 played a crucial role in regulating
the b12 susceptibility of AE-Env clones by cooperating
with two previously reported PNLG sites, N186 and N197,
in the V2 and C2 regions of gp120 [33]. These amino acidTable 8 The infectivity of B-Env clones and the derived mutan
Relativ
Env clone Wild-type N186Q N197Q N186Q/N197Q D18
pNL4-3 100 71 8 0 107
QH0692.42 958 365 118
SC422661.8 657 324 569
pWITO4160.33 49 5
TRO.11 294 69
aInfectivity of Env-recombinant virus was evaluated using U87.CD4.CXCR4 and U87.
with the luciferase activity of pNL-envCT (pNL4-3)-infected U87.CD4.CXCR4 cells, wh
bSingle or multiple amino acid mutations were introduced into B-Env-recombinantpositions were responsible for determining the b12 resist-
ance of 21 of 23 (>91%) AE-Env clones tested. The V1/V2
regions of gp120 contact with CD4 molecule when gp120
binds to CD4 [41,42], and this may account for the role of
V1/V2 regions in regulating viral susceptibility to neutraliz-
ing antibodies against the CD4bs of gp120, including b12
[35,43-46]. Previous computational analysis revealed that
the amino acid residue at position 185 was involved in the
regulation of viral b12 susceptibility [29]. The amino acid
residue at position 185 locates near the C-terminus of
V2 region, where the amino acid sequence is relativelyts
e infectivity (RLU)a
Mutation(s)b
5G D185N D185E E185D D185G/N197Q E185D/N197Q
58 39 0




CD4.CCR5 cells. Relative infectivity of the virus was calculated by comparing it
ich was defined as 100 relative light units (RLU).
viruses. Amino acid numbering is based on HXB2 Env gp120.
Table 9 The VRC01 susceptibility of AE-Env clones containing D185 and the derived mutants
IC50 of VRC01 (μg/ml)
a
Mutation(s)b
Env clone Wild-type N186Q N197Q D185G/N186Q D185G/N197Q
29CC1 >2 c >2 >2
45CC1 >2 0.05 0.09
47PL1 >2 >2 >2
99PB2 0.02 0.10 0.03
99CC8 1.16 0.20 0.06
105PB1 0.07 0.11 0.04
105PL2 >2 0.07 0.09
105PL3 0.25 0.02 0.02
107CC2 0.33 0.15 0.09
aIC50 of VRC01 for suppressing viral replication was calculated using GraphPad Prism 5 software. Data are shown as the means of at least two independent experiments.
bSingle or multiple amino acid mutations were introduced into the AE Env-recombinant virus. Amino acid numbering is based on HXB2 Env gp120.
cIC50 is >2 μg/ml.
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http://www.retrovirology.com/content/11/1/32conserved and affects the interaction of b12 with gp120
molecule [29,41,47]. In the report, G185 was suggested to
be responsible for viral b12 resistance among several sub-
types and CRFs of HIV-1, while D185, E185 or N185 of
gp120 were responsible for viral b12 susceptibility [29].
Our results demonstrated the role of G185 in viral b12 re-
sistance; however, they were partly inconsistent with the
previous report. Namely, the effect of E185 and N185 on
viral b12 susceptibility was not as significant as that of
D185 in our study; therefore, there is a discrepancy be-















21PL2 >2c 0.17 0.0
47CC11 >2 >2 >2




60PB2 0.28 0.08 0.0
60PL2 >2 0.02 0.0
62PL1 >2 >2
65CC4 1.20 0.28 0.32
98CC2 0.38 0.19 0.21
101PL1 0.50 0.04
102CC2 >2 0.35
104PB4 >2 >2 >2
aIC50 of VRC01 for suppressing viral replication was calculated using GraphPad Prism 5
bSingle or multiple amino acid mutations were introduced into AE-Env-recombinan
cIC50 is >2 μg/ml.Our previous report showed that high amino acid vari-
ability was observed in the V2 region, as well as in the V1,
V4 and V5 regions, of Env gp120 among viral genomic
fragments continuously collected for a short period
(3 years) from CRF01_AE-infected Thai individuals [48],
suggesting that the virus constantly evolved by introducing
mutations in the V2 region of gp120, presumably in order
to counteract anti-HIV-1 humoral immune responses. Env
gp120 and gp41 are the major targets of anti-HIV-1 neu-
tralizing antibodies, and are therefore candidates for vac-























software. Data are shown as the means of at least two independent experiments.
t viruses. Amino acid numbering is based on HXB2 Env gp120.
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cine is available [49]. Until recently, only one completed
clinical trial in Thailand, RV144, was shown to have 31.2%
protection efficacy against HIV-1 infection [49-51]. The re-
combinant Env gp120 protein derived from a CRF01_AE
(A244) strain, A244-rgp120, and that derived from a sub-
type B (MN) strain, MN-rgp120, were used as immuno-
gens in the RV144 clinical trial [52] and the majority of
HIV-1 infection in the trial was caused by CRF01_AE
viruses (91.7%) [53], which are the predominant CRF of
HIV-1 prevalent in Thailand [26]. Recent analyses of the
vaccine-induced immune responses in the RV144 trial
showed that the induction level of antibodies against the
V2 region of Env gp120 was inversely correlated with the
infection risk [54-56]. In addition, antibodies against
the V2 region recognized both a conformational epitope
presented on a fusion protein containing the V1 and V2
regions of gp120, gp70-V1V2, as well as a linear epitope lo-
cated at amino acid residues 165-178 in the V2 region [55],
while a lysine residue at position 169 (K169) and an isoleu-
cine residue at position 181 (I181) in the V2 region played
an important role in determining vaccine efficacy [57].
These studies suggest that immunodominant regions lo-
cated in the V2 region of Env gp120 are an effective target
of protective immune response against CRF01_AE viruses,
and the introduction of mutations into a few amino acid
residues in the V2 region significantly affect the effective-
ness of vaccine-induced anti-V2 neutralizing antibodies.
Our study revealed that the major determinants of resist-
ance to a CD4bs antibody, b12, were located in the V2
region of Env gp120 derived from CRF01_AE viruses.
Therefore, we believe that further understanding of how
amino acid mutations in the V2 region of Env gp120 affect
the neutralization susceptibility of currently circulating
CRF01_AE viruses to vaccine candidate-induced neutraliz-
ing antibodies as well as to established broadly reactive
nhmAbs may provide important information to develop
effective HIV-1 vaccines.
Our recent study showed that plasma samples derived
from infected Thai individuals efficiently neutralize AE-
Env-recombinant viruses, while the samples poorly neu-
tralized B-Env- and C-Env-recombinant viruses [58],
consistent with the results described in a previous report
that serum samples derived from subtypes B and E
(CRF01_AE)-infected Thai individuals showed subtype-
specific neutralizing activity [59]. These results suggest a
difference in the antigenicity of Env gp120 and gp41
among CRF01_AE, subtype B and C viruses. In addition,
the AE-Env immunogen, A244-rgp120, is suggested to
be able to induce a stronger antibody response against
the V2 region than the B-Env immunogen, MN-rgp120,
in the RV144 trial [55,60]; therefore, the immunogenicity
of the V2 region of Env gp120 might also differ between
CRF01_AE and subtype B viruses. Env gp120 is the mostvariable HIV-1 protein with typical intersubtype and
intrasubtype differences soaring to 35% and 20%, re-
spectively [61]. In addition, structural differences of the
conserved and variable regions of Env gp120 are re-
ported between subtype B and C Env molecules [62,63],
while our previous study suggested that different Env re-
gions are affected by host immune pressure between
CRF01_AE and subtype B viruses [48]. Therefore, the
structure of Env gp120 is somewhat different among di-
verse HIV-1 subtypes and CRFs. The b12 antibody rec-
ognizes a conformational epitope on gp120; thus, b12
susceptibility of the virus is necessarily affected by the
protein structure of gp120. Our results showed that the
amino acid residue at position 185 in the V2 region of
Env gp120 played a major role in b12 susceptibility of
AE-Env clones, but not of B-Env clones, suggesting that
the structure of the V2 region may differ between
CRF01_AE and subtype B viruses. Although the struc-
ture of the V2 region of Env gp120 derived from subtype
C viruses is already determined [64], that of CRF01_AE
has not been determined; therefore, we consider that it
is important to solve the protein structure of AE-Env
gp120 in order to design an effective vaccine antigen
against CRF01_AE viruses. Since the structure of AE-
Env gp120 including the V2 region is currently not avail-
able, it is difficult to discuss the structural aspects of the
role of the amino acid residue at position 185 and 2
PNLG sites, N186 and N197, in regulating the b12 sus-
ceptibility of AE-Env clones; however, the potential
effects of these amino acid substitutions on Env struc-
ture is as follows. According to the structural studies on
BG505 SOSIP.664 gp140 derived from a subtype A
strain, BG505, the glycan attached at the position 197 of
gp120 contacts with the V3 region of neighboring gp120
molecule in Env trimeric structure, and is suggested to
avoid the premature release of V3 region before the
binding of gp120 to CD4 [65]. In addition, the removal
of N197 from subtypes B and C Env proteins is reported
to increase viral susceptibility to neutralizing antibodies
including b12 [31,35,43,66,67], and this may be due to
the changing in the quaternary structure of Env trim-
mers which leads to increase the accessibility of anti-
bodies to the epitopes. The removal of N197 might
reduce the stability of CD4-unbounded Env proteins and
possibly decreases viral infectivity. However, the removal
of N186 and N197, as well as the introduction of a mu-
tation at amino acid position 185, did not significantly
reduce the infectivity of most AE-Env-recombinant
viruses (Tables 6 and 7), indicating that these AE-Env
clones maintained the functional Env structure in the
presence of these mutations. However, the binding of
b12 to AE-Env proteins was significantly improved by the
introduction of double mutations, G185D, N185D or
E185D together with N197Q, but not by the introduction
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sidering these results, the introduction of an amino acid
substitution at position 185 and the removal of N197
might synergistically alter the trimeric structure of AE-
Env proteins and lead to increase the binding efficiency of
b12 to Env proteins. We believe that our results might
provide important information to take into account the
antigenic and immunogenic diversity of Env gp120 among
different subtypes and CRFs of HIV-1 to develop an effect-
ive HIV-1 vaccine.
Conclusion
In this report, we show that the amino acid residue at
position 185 and 2 PNLG sites in the V2 and C2 regions
of AE-Env gp120 are the major determinants of viral
resistance to CD4bs antibodies. We believe that our data
may provide important information to understand the mo-
lecular mechanism regulating the neutralization suscepti-
bility of HIV-1 CRF01_AE viruses to CD4bs antibodies as
well as to design vaccine antigens against these viruses.
Methods
Cells
293T cells were maintained in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum (10%
FBS-DMEM). U87.CD4.CCR5 and U87.CD4.CXCR4 cells
were obtained from Drs. HongKui Deng and Dan R.
Littman through the AIDS Research and Reference Reagent
Program (ARRRP) (Division of AIDS, NIAID, NIH), and
were maintained in 10% FBS-DMEM with puromycin
(1 μg/ml) and G418 (300 μg/ml) (complete medium).
Preparation of recombinant proviral constructs
cDNAs encoding full-length AE-Env gp120 and gp41
were cloned into pNL-envCT [68], a luciferase reporter
proviral DNA derived from pNL4-3 [69], to generate AE-
Env-recombinant proviral constructs as described previ-
ously [32]. In addition, full-length subtype B env clones,
QH0692.42, TRO.11, pWITO4160.33 and SC422661.8
[70], obtained from Drs. Feng Gao, Beatrice H. Hahn, Ming
Li, David C. Montefiori and Jesus F. Salazar-Gonzalez
through the ARRRP, were cloned into pNL-envCT to gen-
erate B-Env-recombinant proviral constructs as described
previously [58]. In order to generate N-linked glycosylation
mutants, N186Q, N197Q, N301Q, N339Q, N386Q and/or
N392Q, were introduced into proviral constructs by site-
directed mutagenesis using the QuikChange site-directed
mutagenesis kit (Agilent Technologies, Santa Clara, CA). In
addition, single or multiple amino acid mutation(s), H144L,
D185G, D185N, D185E, G185D, N185D, E185D, del.NIND
(deletion of 4 amino acid residues, NIND), N189S, I190T,
ins.D460 (insertion of D460), I467T, V488I and/or R500M,
were introduced into proviral constructs by site-directed
mutagenesis.Detection of PNLG site in the deduced amino acid
sequence of HIV-1 env gene
PNLG sites in HIV-1 env genes were examined using
N-Glycosite (www.hiv.lanl.gov).Preparation of recombinant virus
Viral supernatant was prepared by transfecting 293 T
cells with a proviral construct using FuGENE HD trans-
fection reagent (Roche, Basel, Switzerland). Forty-eight
hours after transfection, the supernatant was cleared by
centrifugation for 5 min at 8,000 rpm, and stored in ali-
quots at −85°C. The concentration of HIV-1 Gag p24 anti-
gen in viral supernatants was measured by enzyme-linked
immunosorbent assay (ELISA) (HIV-1 p24 Antigen Cap-
ture Assay; Advanced Bioscience Laboratory, Rockville,
MD). The relative infectivity of recombinant viruses con-
taining wild-type or mutant Env clones was examined, as
follows. U87.CD4.CXCR4 or U87.CD4.CCR5 cells, which
were seeded into a 24-well plate (3 × 104 cells per 500 μl
per well) 24 h prior to the tests, were infected with recom-
binant viruses (10 ng of p24 antigen). U87.CD4.CXCR4
cells were used as target cells for recombinant viruses con-
taining CXCR4-tropic (X4) or dual-tropic (X4R5) Env,
whereas U87.CD4.CCR5 cells were used as target cells for
the viruses containing CCR5-tropic (R5) Env. Forty-eight
hours after infection, luciferase activity in infected cells
was measured using the Steady Glo Luciferase assay kit
(Promega, Madison, WI) with an LB960 microplate
luminometer (Berthold, Bad Wildbad, Germany). Relative
infectivity of the recombinant virus was calculated by
comparing it with the luciferase activity of pNL-envCT
(pNL4-3)-infected U87.CD4.CXCR4 cells, which was de-
fined as 100 relative light units (RLU).Neutralization tests
Neutralization susceptibilities of a recombinant virus to
nhmAbs against the CD4bs of Env gp120, b12 (Polymun
Scientific, Vienna, Austria) and VRC01 (obtained from
Dr. John Mascola through the ARRRP), were examined
as follows. Viral supernatants (5 ng of p24 antigen) were
incubated with 2-fold serially diluted monoclonal anti-
body, b12 or VRC01, in 100 μl complete medium for 1 h
at 37°C. U87.CD4.CXCR4 or U87.CD4.CCR5 cells, which
were seeded into a 96-well plate (5 × 103 cells per 100 μl
per well) 24 h prior to neutralization tests, were then incu-
bated with the mixture of viral supernatants and the anti-
body. Forty-eight hours after infection, luciferase activity
in infected cells was measured as described above. Percent
neutralization was calculated by determining the reduc-
tion in luciferase activity in the presence of the monoclo-
nal antibody, b12 or VRC01, compared to that in control
experiments in the absence of the antibody. The IC50 of
the monoclonal antibody for suppressing viral replication
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Prism 5 software (GraphPad Software, San Diego, CA).
Binding assay
The binding efficiency of a recombinant virus to the
monoclonal antibody, b12 was examined as follows. The
antibody, b12 (5 μg) was incubated with protein G-
conjugated magnetic beads, Dynabeads Protein G (0.3 mg)
(Life Technologies, Lillestrom, Norway) with rotation for
24 h at 4°C in 400 μl phosphate-buffered saline (PBS), to
generate b12-magnetic bead complex. After washed with
PBS using the Dynal MPC-S Magnetic Particle Concentra-
tor (Invitrogen Dynal, Oslo, Norway), the b12-magnetic
bead complex was incubated with viral supernatants
(2.5 ng of p24 antigen) with rotation for 24 h at 4°C in
100 μl of PBS. In a control experiment, viral supernatants
containing an Env-deficient virus (2.5 ng of p24 antigen),
that was generated from an env-deficient proviral construct,
pNL-Luc-E−R+ [71], was incubated with the b12-magnetic
bead complex. Twenty-four hours after incubation, the
virus-b12-magnetic bead complex was extensively washed
with PBS and then HIV-1 Gag p24 antigen associated with
the complex was measured by ELISA as described above.
The percent recovery of Gag p24 antigen was calculated
after subtracting the p24 antigen value associated with the
virus-b12-magnetic bead complex in the control experiment
using Env-deficient virus. Statistical analysis was carried out
using a standard function of GraphPad Prism 5 software
(GraphPad Software, San Diego, CA) with a Paired t test.
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